Medicare disease management
Executive Summary
Demonstration disease management project with Medicare fee-for-service beneficiaries gets under way in Oklahoma, with a program run by Lifemasters, and in Washington, D.C. and Maryland, with an American Healthways program. Both began Aug. 1. CMS announced Aug. 2 that the Medicare Health Support pilot programs will begin later in August in Western Pennsylvania (Health Dialog) and Mississippi (McKesson Health Solutions) and in the fall in Northwest Georgia (CIGNA), Chicago (Aetna), Central Florida (Humana) and Tennessee (XLHealth). Details are still being worked out for the Brooklyn/Queens, N.Y. demonstration site with the Visiting Nurse Service of New York and United HealthCare Services-Evercare. Mandated by the Medicare Modernization Act, the project focuses on providing a variety of disease management tools, such as nurse coaching and drug compliance reminders, for patients with diabetes or congestive heart failure. The demonstration is reviewed in depth in a new report, Disease Management, Medicare Modernization and the Keys to Success, produced by Datamonitor in association with F-D-C Reports (1fdcreports.com/diseasemanagement)...
You may also be interested in...
LifeMasters Disease Management Demo Includes Reports To Physicians
Disease management company LifeMasters' Medicare demonstration project provides quarterly reports to physicians listing all of a patient's prescriptions plus over-the-counter medications and alternative therapies
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.